Evotec (EVO) Competitors $3.76 +0.05 (+1.21%) As of 10:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVO vs. LNTH, RYTM, AXSM, TLX, CRSP, PCVX, CYTK, MTSR, ADMA, and KRYSShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Cytokinetics (CYTK), Metsera (MTSR), ADMA Biologics (ADMA), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Its Competitors Lantheus Rhythm Pharmaceuticals Axsome Therapeutics Telix Pharmaceuticals CRISPR Therapeutics Vaxcyte Cytokinetics Metsera ADMA Biologics Krystal Biotech Evotec (NASDAQ:EVO) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Do insiders & institutionals hold more shares of EVO or LNTH? 5.8% of Evotec shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 2.0% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend EVO or LNTH? Evotec presently has a consensus price target of $5.93, suggesting a potential upside of 57.59%. Lantheus has a consensus price target of $131.20, suggesting a potential upside of 81.15%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Lantheus 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has higher valuation & earnings, EVO or LNTH? Lantheus has higher revenue and earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$788.22M1.70-$212.18MN/AN/ALantheus$1.53B3.27$312.44M$3.5220.58 Does the media refer more to EVO or LNTH? In the previous week, Lantheus had 13 more articles in the media than Evotec. MarketBeat recorded 20 mentions for Lantheus and 7 mentions for Evotec. Lantheus' average media sentiment score of 0.97 beat Evotec's score of 0.08 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is EVO or LNTH more profitable? Lantheus has a net margin of 16.55% compared to Evotec's net margin of -26.34%. Lantheus' return on equity of 36.99% beat Evotec's return on equity.Company Net Margins Return on Equity Return on Assets Evotec-26.34% -21.51% -10.54% Lantheus 16.55%36.99%20.55% Which has more risk & volatility, EVO or LNTH? Evotec has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. SummaryLantheus beats Evotec on 13 of the 14 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.34B$2.49B$5.61B$9.42BDividend YieldN/A1.80%4.01%4.02%P/E RatioN/A9.2228.3620.00Price / Sales1.70580.60414.8086.63Price / CashN/A165.2635.9658.29Price / Book1.295.088.425.73Net Income-$212.18M$30.99M$3.24B$258.18M7 Day Performance-10.78%3.09%4.13%3.46%1 Month Performance-1.18%14.27%12.22%14.30%1 Year Performance-21.23%-1.13%34.98%18.46% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec2.089 of 5 stars$3.77+1.2%$5.93+57.6%-24.4%$1.34B$788.22M0.004,827News CoverageLNTHLantheus4.7007 of 5 stars$83.06+2.2%$131.20+58.0%-36.9%$5.75B$1.53B23.60700Upcoming EarningsRYTMRhythm Pharmaceuticals3.2799 of 5 stars$89.15+2.8%$91.00+2.1%+76.4%$5.67B$130.13M-31.73140AXSMAxsome Therapeutics4.6892 of 5 stars$112.33+3.1%$172.33+53.4%+19.2%$5.53B$385.69M-19.47380TLXTelix PharmaceuticalsN/A$15.57-2.5%$22.33+43.4%N/A$5.27B$783.21M0.00N/ANews CoverageCRSPCRISPR Therapeutics1.7603 of 5 stars$56.42-0.7%$71.75+27.2%+17.2%$4.87B$37.31M-12.48460Analyst ForecastAnalyst RevisionPCVXVaxcyte1.8571 of 5 stars$36.38+1.3%$136.50+275.2%-57.5%$4.69BN/A-9.12160Positive NewsCYTKCytokinetics4.2443 of 5 stars$38.58+4.2%$70.92+83.8%-34.3%$4.61B$18.47M-7.29250MTSRMetseraN/A$42.47+8.1%$55.00+29.5%N/A$4.46BN/A0.0081Gap DownADMAADMA Biologics3.8878 of 5 stars$18.68+0.9%$27.67+48.1%+24.0%$4.46B$426.45M21.98530Positive NewsKRYSKrystal Biotech4.8342 of 5 stars$150.41+1.5%$213.75+42.1%-26.6%$4.35B$290.52M36.16210Analyst Forecast Related Companies and Tools Related Companies Lantheus Alternatives Rhythm Pharmaceuticals Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Alternatives CRISPR Therapeutics Alternatives Vaxcyte Alternatives Cytokinetics Alternatives Metsera Alternatives ADMA Biologics Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVO) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.